CSL keeps pumping up the profit

Original article by Jared Lynch
The Australian – Page: 17 & 27 : 13-Feb-20

CSL has posted a 2019-20 interim net profit of $US1.248bn, which is eight per cent higher than previously. Sales rose by 8.4 per cent to $US4.7bn, with sales of its immunoglobulin products rising by 26 per cent to $US1.985bn. The biotechnology group expects its full-year profit to be within the range of $US2.1bn to $US2.17bn. CEO Paul Perreault says none of the company’s employees in Wuhan have been infected by the coronavirus and the company has not yet been impacted by the outbreak.

CORPORATES
CSL LIMITED – ASX CSL

Why 30,000 cases of cancer are over-diagnosed in Australia every year

Original article by Jill Margo
The Australian Financial Review – Page: Online : 28-Jan-20

Almost 30,000 cases of cancer may be over-diagnosed in Australia each year, according to a study published in the ‘Medical Journal of Australia’. Those involved in the study contend that eliminating over-diagnosis altogether is unlikely, but changes in public health policy are needed to help reduce the incidence of it. The term ‘over-diagnosis’ refers to the detection of cancers that, if left untreated, would not turn out to be life-threatening for the person concerned. Cancer Council Australia CEO Sanchia Aranda suggests that most people would prefer over-diagnosis of cancer to under-diagnosis.

CORPORATES
CANCER COUNCIL OF AUSTRALIA

Patients wait too long for life-saving care – report

Original article by Nicole Hasham
The Sydney Morning Herald – Page: 11 : 10-Dec-14

The Auditor-General’s office in New South Wales (NSW) has issued the latest survey of public hospital emergency department performance. It shows an improvement on 2013, despite a rise in patient numbers to close to 2.7 million. However waiting times at hospitals in the Sydney, Central Coast and Western NSW health districts were unacceptably long, as the facilities failed to meet the standard of four fifths of patients being treated within 10 minutes. Ambulance response times meanwhile have fallen to 10.8 minutes, in the biggest improvement since 2009

CORPORATES
NEW SOUTH WALES. AUDITOR GENERAL’S DEPT, NEW SOUTH WALES. MINISTRY OF HEALTH, GOSFORD HOSPITAL, ROYAL PRINCE ALFRED HOSPITAL, CONCORD HOSPITAL, CANTERBURY HOSPITAL, AMBULANCE SERVICE OF NEW SOUTH WALES, AUSTRALIAN LABOR PARTY

Ambulance waiting times getting longer

Original article by Julia Medew, Craig Butt
The Age – Page: 2 : 10-Dec-14

A court bid under Freedom of Information laws has resulted in the paramedics’ union gaining access to statistics kept by Ambulance Victoria. The data show that ambulance response times have deteriorated, with 86,739 patients in a serious condition having to wait more than a quarter of an hour in 2013. This was equivalent to some 28% of all such cases, and an increase from the 19% recorded in the 2010 study by the Victorian Auditor-General. The newly-elected State Government has vowed to lift spending on the ambulance service by $A100m

CORPORATES
AMBULANCE VICTORIA FIRST AID, AMBULANCE EMPLOYEES AUSTRALIA, VICTORIA. DEPT OF HEALTH, VICTORIA. AUDITOR-GENERAL’S OFFICE, AUSTRALIAN LABOR PARTY

Immunotherapy a groundbreaking new cancer treatment, but prohibitively expensive

Original article by Tracy Bowden
abc.net au – Page: Online : 10-Sep-19

Developed by Swiss company Novartis, Kymriah is an innovative immunotherapy treatment that has been described by University of NSW cancer biologist Darren Saunders as a type of living drug. Saunders notes it has shown to be very beneficial for a large number of people with certain types of leukaemia and lymphoma, but not all patients. Dave Roberts, who has a type of lymphoma, says his doctor has told him that Kymriah is basically his only hope of survival. The federal government is not yet funding Kymriah for people with the type of cancer that Roberts has, so treatment would cost him $500,000.

CORPORATES
NOVARTIS AG, UNIVERSITY OF NEW SOUTH WALES

China’s $2b swoop on health giant

Original article by Carrie LaFrenz
The Australian Financial Review – Page: 1 & 6 : 4-Jan-19

Shares in pathology, imaging and medical centres operator Healius closed 7.8 per cent higher at $2.63 on 3 January, in response to a takeover bid from Jangho Group. The Chinese company already has a 15.93 per cent stake in Healius and is offering $3.25 per share. Healius, which changed its name from Primary Health Care in late 2018, has advised shareholders to take no action regarding the unsolicited offer at present. It has stressed that Jangho’s approach may not necessarily result in a deal.

CORPORATES
HEALIUS LIMITED – ASX HLS, JANGHO GROUP, VISION EYE INSTITUTE LIMITED, MONASH IVF GROUP LIMITED – ASX MVF, HEALTHSCOPE LIMITED – ASX HSO, MACQUARIE GROUP LIMITED – ASX MQG, CHEUNG KONG INFRASTRUCTURE HOLDINGS LIMITED, APA GROUP – ASX APA, HUAWEI TECHNOLOGIES COMPANY LIMITED, AUSTRALIAN PHARMACEUTICAL INDUSTRIES LIMITED – ASX API, SIGMA HEALTHCARE LIMITED – ASX SIG, AUSTRALIA. FOREIGN INVESTMENT REVIEW BOARD, AUSTRALIAN SECURITIES AND INVESTMENTS COMMISSION, AUSTRALIA. FAIR WORK COMMISSION, KING AND WOOD MALLESONS, UBS HOLDINGS PTY LTD

Fitness tests for ageing doctors

Original article by Sean Parnell
The Australian – Page: 5 : 29-Nov-17

The Medical Board of Australia has recommended that doctors over the age of 70 be required to undergo fitness testing to ensure they are still capable of treating patients. However, Board chairwoman Joanna Flynn stressed that there were no plans to introduce a mandatory retirement age for doctors. The Board also wants registered doctors to undertake a minimum of 50 hours of continuing professional development each year, while it would like to see young doctors and medical students observed "for possible integrity issues"

CORPORATES
MEDICAL BOARD OF AUSTRALIA

Breath test to detect malaria

Original article by John Ross
The Australian – Page: 9 : 7-Nov-17

Biologists at Washington University in the US state of Missouri have developed a procedure for detecting signs of malaria in infected people’s breath. They trialled their procedure on patients in a children’s clinic in Malawi. When breath samples were returned to the US for testing, it was found they had correctly diagnosed 83 per cent of those already known to be carrying the disease as a result of blood tests. Australian researchers have previously observed high levels of certain chemicals being exhaled by malaria sufferers.

CORPORATES
WASHINGTON UNIVERSITY,CSIRO,BILL AND MELINDA GATES FOUNDATION,AMERICAN SOCIETY OF TROPICAL MEDICINE AND HYGIENE

Swisse parent takes full ownership

Original article by Simon Evans
The Australian Financial Review – Page: 15 & 20 : 16-Dec-16

Biostime International has paid $A311m to acquire the 17 per cent of Swisse that it did not already own following its takeover of the Australian vitamin maker in 2015. Former Treasury Wines Estate executive Oliver Horn has been appointed as MD of Swisse after CEO Radek Sali advised that he will depart at the end of 2016. Sali is one of the minority shareholders who agreed to accept the buyout offer. He says the process of integrating Swisse with Biostime has gone well.

CORPORATES
SWISSE WELLNESS PTY LTD, BIOSTIME INTERNATIONAL HOLDINGS LIMITED, TREASURY WINE ESTATES LIMITED – ASX TWE, PENFOLDS WINES PTY LTD, DIAGEO PLC, FOSTER’S GROUP LIMITED, BELLAMY’S AUSTRALIA LIMITED – ASX BAL, VITACO HOLDINGS LIMITED – ASX VIT, SHANGHAI PHARMACEUTICAL HOLDING COMPANY LIMITED, PRIMAVERA CAPITAL GROUP, BLACKMORES LIMITED – ASX BKL, NATURE’S CARE

CSL shrugs off growth concerns, shares slide

Original article by Ben Potter
The Australian Financial Review – Page: 17 & 22 : 18-Aug-16

CSL has posted a 2015-16 net profit of $US1.24bn ($A1.6bn), which is 10 per cent lower than previously. The blood products and vaccines group’s sales rose by eight per cent to $US6.13bn. Earnings per share fell by eight per cent to $US2.69, but increased by seven per cent on a constant currency basis. CSL has forecast underlying net profit and EBITDA growth of 11 per cent and 14 per cent respectively in 2016-17. Its shares closed five per cent lower at $A110.84 on 17 August 2016.

CORPORATES
CSL LIMITED – ASX CSL, SHIRE PHARMACEUTICALS GROUP PLC, NOVARTIS AG, CSL BEHRING, WILSONS ADVISORY AND STOCKBROKING LIMITED, SEQIRUS PTY LTD